Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Verizon Communications Inc (VZ) Price & Performance

Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Verizon Communications Inc — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Verizon Communications Inc trades at $46.96 (market cap $196.40B). The key difference: Verizon Communications Inc is the larger of the two by market cap, and Verizon Communications Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.

SNYVZ
Market Cap
$104.30B$196.40B
Sector
HealthMedia
52-Week High
$52.34$51.38
52-Week Low
$41.33$38.40
Enterprise Value
$124.19B$383.10B
Dividend Yield
5.55%5.99%
Volume
22,584,735

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Verizon Communications Inc

Verizon (VZ) trades at $46.93, down slightly by 0.21% on the day, with a bullish technical signal from moving averages. The company shows stable fundamentals with $138.19B in 2025 revenue and consistent earnings beats in recent quarters. Recent news highlights network expansion initiatives and strategic partnerships, including a fiber deal with Alphabet. Cash flow improved significantly in 2025 with $14.86B net cash flow, though debt levels remain elevated at $121.38B long-term.

VZ presents a value opportunity with a P/E of 12.31 below sector average and strong dividend yield. Analyst consensus targets $49.69 with 36.7% buy ratings, though competition from SpaceX's Starlink and high debt pose risks. The stock's current price near support at $47 suggests limited downside if technical levels hold.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ